Government investment in cell and gene therapy sector bears fruit

A decade on from the founding of The Cell and Gene Therapy Catapult (CGT Catapult), the UK-based industry accelerator is celebrating its successes.

With the publication of its  annual review, the group aims to highlight the continued development of the UK cell and gene therapy sector, with 31% growth in funds raised by British advanced therapy developers of £1.7 billion ($2.03 billion).

There has also been a 25% increase in manufacturing space in the UK for this type of therapy over the last 12 months, thanks to an ongoing and increasing number of partnerships.